Evaluation of plasma IL-21 as a potential biomarker for type 1 diabetes progression

Front Immunol. 2023 Jun 21:14:1157265. doi: 10.3389/fimmu.2023.1157265. eCollection 2023.

Abstract

IL-21 is a multifunctional cytokine linked with the pathophysiology of several autoimmune diseases, including type 1 diabetes. In this study, our aim was to examine plasma IL-21 levels in individuals at different stages of type 1 diabetes progression. We measured plasma IL-21 levels, as well as levels of other key pro-inflammatory cytokines (IL-17A, TNF-α and IL-6), from 37 adults with established type 1 diabetes and 46 healthy age-matched adult controls, as well as from 53 children with newly diagnosed type 1 diabetes, 48 at-risk children positive for type 1 diabetes-associated autoantibodies and 123 healthy age-matched pediatric controls using the ultrasensitive Quanterix SiMoA technology. Adults with established type 1 diabetes had higher plasma IL-21 levels compared to healthy controls. However, the plasma IL-21 levels showed no statistically significant correlation with clinical variables, such as BMI, C-peptide, HbA1c, or hsCRP levels, evaluated in parallel. In children, plasma IL-21 levels were almost ten times higher than in adults. However, no significant differences in plasma IL-21 levels were detected between healthy children, autoantibody-positive at-risk children, and children with newly diagnosed type 1 diabetes. In conclusion, plasma IL-21 levels in adults with established type 1 diabetes were increased, which may be associated with autoimmunity. The physiologically high plasma IL-21 levels in children may, however, reduce the potential of IL-21 as a biomarker for autoimmunity in pediatric subjects.

Keywords: IL-21; autoimmune diseases; autoimmunity; human; interleukin-21; type 1 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Autoantibodies
  • Biomarkers
  • Child
  • Cytokines
  • Diabetes Mellitus, Type 1*
  • Humans
  • Interleukin-17*
  • Interleukins

Substances

  • Autoantibodies
  • Biomarkers
  • Cytokines
  • Interleukin-17
  • interleukin-21
  • Interleukins
  • IL21R protein, human

Grants and funding

This work was supported by the Academy of Finland (decision no. 331282) and the Sigrid Jusélius Foundation.